-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Acadia Pharmaceuticals, Raises Price Target to $38

Benzinga·11/06/2026 19:50:09
Listen to the news
Canaccord Genuity analyst Sumant Kulkarni maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $36 to $38.